Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.64 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057237 | 0.87 | CHRM4 (0.52) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3052695 | 0.86 | ADORA2B (0.66) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3052315 | 0.85 | ADORA2B (0.67) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3053477 | 0.84 | ALDH1A1 (0.51) | DUSP3CHRM4 | |
| SCHEMBL3046956 | 0.83 | MAPT (0.52) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3046497 | 0.83 | CHRM4 (0.56) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3058897 | 0.82 | ADORA2B (0.53) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3052970 | 0.81 | ADORA2B (0.63) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3053492 | 0.81 | ADORA2B (0.63) | ADORA2BADORA2AADORA1DUSP3CHRM4 | |
| SCHEMBL3052323 | 0.80 | ADORA2B (0.64) | ADORA2BADORA2AADORA1DUSP3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303272-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | claimed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | claimed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | claimed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | claimed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | claimed |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-29 | — | — | US | disclosed |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-08 | — | — | US | disclosed |
| EP-1303272-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1797878-A2 | Benzothiazole derivatives | F. Hoffmann-La Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER | 2006-01-05 | — | — | US | disclosed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.